Skip to Content

New Drug Approvals

The following drugs have recently been approved by the FDA. Includes newly approved drugs and new indications for drugs already approved.

See also: Generic Approvals, Approval Process, New Indications and Dosage forms

Nayzilam (midazolam) Nasal Spray

Company: UCB, Inc.
Date of Approval: May 17, 2019
Treatment for: Seizure Clusters

Nayzilam (midazolam) is a nasally administered benzodiazepine indicated for the acute treatment of seizure clusters.

Ruzurgi (amifampridine) Tablets

Company: Jacobus Pharmaceutical Company Inc.
Date of Approval: May 6, 2019
Treatment for: Lambert-Eaton Myasthenic Syndrome

Ruzurgi (amifampridine) is a potassium-channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years to less than 17 years of age.

Vyndaqel (tafamidis meglumine)

Company: Pfizer Inc.
Date of Approval: May 3, 2019
Treatment for: Cardiomyopathy of Transthyretin-Mediated Amyloidosis

Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis.

Qternmet XR (dapagliflozin, metformin hydrochloride and saxagliptin) Extended-Release Tablets

Company: AstraZeneca
Date of Approval: May 2, 2019
Treatment for: Diabetes Type 2

Qternmet XR (dapagliflozin, metformin hydrochloride and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, biguanide and dipeptidyl peptidase-4 (DPP-4) inhibitor combination indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Dengvaxia (dengue tetravalent vaccine, live) Injection

Company: Sanofi Pasteur, Inc.
Date of Approval: May 1, 2019
Treatment for: Prevention of Dengue Disease

Dengvaxia (dengue tetravalent vaccine, live) is a vaccine indicated for the prevention of dengue caused by dengue virus serotypes 1, 2, 3 and 4 in people 9 years through 16 years of age living in endemic areas who have laboratory-confirmed previous dengue infection.

Duobrii (halobetasol propionate and tazarotene) Lotion

Company: Bausch Health Companies Inc.
Date of Approval: April 25, 2019
Treatment for: Plaque Psoriasis

Duobrii (halobetasol propionate and tazarotene) is a corticosteroid and retinoid combination indicated for the topical treatment of plaque psoriasis.

Eticovo (etanercept-ykro) Injection

Company: Samsung Bioepis Co., Ltd.
Date of Approval: April 25, 2019

Eticovo (etanercept-ykro) is a tumor necrosis factor (TNF) blocker biosimilar to Enbrel indicated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.

Skyrizi (risankizumab-rzaa) Injection

Company: AbbVie Inc.
Date of Approval: April 23, 2019
Treatment for: Plaque Psoriasis

Skyrizi (risankizumab-rzaa) is an interleukin-23 (IL-23) inhibitor for the treatment of plaque psoriasis.

Balversa (erdafitinib) Tablets

Company: Janssen Pharmaceuticals, Inc.
Date of Approval: April 12, 2019
Treatment for: Urothelial Carcinoma

Balversa (erdafitinib) is a once-daily, oral, pan-fibroblast growth factor receptor for the treatment of patients with locally advanced or metastatic urothelial cancer.

Plenity (cellulose and citric acid) Capsules

Company: Gelesis
Date of Approval: April 12, 2019
Treatment for: Obesity

Plenity (cellulose and citric acid) is an oral, non-systemic, superabsorbent hydrogel used in conjunction with diet and exercise to aid weight management in adults who are overweight or obese. It works by inducing a feeling of fullness so that patients eat less and lose weight.

Evenity (romosozumab-aqqg) Injection

Company: Amgen Inc.
Date of Approval: April 9, 2019
Treatment for: Osteoporosis

Evenity (romosozumab) is an anti-sclerostin monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture.

Dovato (dolutegravir and lamivudine) Tablets

Company: ViiV Healthcare
Date of Approval: April 8, 2019
Treatment for: HIV Infection

Dovato (dolutegravir and lamivudine) is a once-daily, single-tablet, two-drug regimen of the approved drugs dolutegravir (Tivicay) and lamivudine (Epivir) indicated for the treatment of HIV-1 infection in adults with no antiretroviral (ARV) treatment history and with no known resistance to either dolutegravir or lamivudine.

Asceniv (immune globulin intravenous, human – slra) Injection

Company: ADMA Biologics, Inc.
Date of Approval: April 1, 2019
Treatment for: Primary Immunodeficiency Syndrome

Asceniv (immune globulin intravenous, human – slra) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI).

Mavenclad (cladribine) Tablets

Company: EMD Serono, Inc.
Date of Approval: March 29, 2019
Treatment for: Multiple Sclerosis

Mavenclad (cladribine) is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis (MS).

Duaklir Pressair (aclidinium bromide and formoterol fumarate) Inhalation Powder

Company: Circassia Pharmaceuticals plc
Date of Approval: March 29, 2019
Treatment for: Chronic Obstructive Pulmonary Disease

Duaklir Pressair (aclidinium bromide and formoterol fumarate) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2 agonist (LABA) fixed dose combination maintenance bronchodilator for the treatment of COPD.

Avaclyr (acyclovir) Ophthalmic Ointment

Company: Fera Pharmaceuticals
Date of Approval: March 29, 2019
Treatment for: Herpes Simplex Dendritic Keratitis

Avaclyr (acyclovir ophthalmic ointment) is a herpes simplex virus nucleoside analog DNA polymerase inhibitor indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.

Jatenzo (testosterone undecanoate) Capsules

Company: Clarus Therapeutics, Inc.
Date of Approval: March 27, 2019
Treatment for: Hypogonadism -- Male

Jatenzo (testosterone undecanoate) is an oral testosterone replacement therapy for the treatment of low testosterone in hypogonadal men.

Mayzent (siponimod) Tablets

Company: Novartis Pharmaceuticals Corporation
Date of Approval: March 26, 2019
Treatment for: Multiple Sclerosis

Mayzent (siponimod) is a sphingosine-1-phosphate receptor modulator for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Sunosi (solriamfetol) Tablets

Company: Jazz Pharmaceuticals plc
Date of Approval: March 20, 2019
Treatment for: Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome

Sunosi (solriamfetol) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI) for the treatment of excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).

Zulresso (brexanolone) Injection

Company: Sage Therapeutics
Date of Approval: March 19, 2019
Treatment for: Postpartum Depression

Zulresso (brexanolone) is a gamma-aminobutyric acid A (GABAA) receptor positive allosteric modulator indicated for the treatment of postpartum depression (PPD).

Older articles

FDA Drug Approvals Archive

More News Resources

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.